Dupixent front and center of Sanofi's lofty immunology ambitions

31 March 2022

French drugmaker Sanofi (Euronext: SAN) held an investor event this week to outline its ambitions in the immunology space, including the goal to more than quadruple sales in this space by 2030.

The focus of the event was on Dupixent (dupilumab) as a key growth driver, along with Sanofi’s broader pipeline, underlining the importance of dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas for the company.

Sanofi has raised the Dupixent sales peak ambition to more than 13 billion euros ($14.4 billion), where in 2021 the drug’s revenue was 5.25 billion euros. This new target does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK